Is NMN Still Legal? The FDA Supplement Question, Answered

Short answer: As of August 2026, NMN is marketed as a U.S. dietary supplement again. The FDA excluded it on November 4, 2022 over the drug-exclusion clause, reversed that position on September 29, 2025, and restored NMN's NDI acknowledgment eligibility on December 2, 2025. Not legal advice — the status can change.

If you've seen conflicting answers to "is NMN legal," you're not imagining it — the answer genuinely changed, twice, within three years, and much of the content ranking for this query still carries the pre-reversal framing. The good news is that the most recent chapter is a positive one. This page lays out the dated timeline, what the reversal opened up, and why we sell no NMN product regardless. This is educational content, not legal advice; for anything involving your business or compliance exposure, consult a licensed attorney. How we vet and document everything we carry is laid out in the safety and sourcing pillar.

The timeline, with dates

• Before 2022: NMN (nicotinamide mononucleotide) was marketed in the U.S. as a dietary supplement, sold as an NAD+ precursor.
• November 4, 2022: The FDA excluded NMN from the dietary-supplement definition via NDI response letters (to SyncoZymes, NDIN 1247, and Inner Mongolia Kingdomway, NDIN 1259) under the 21 U.S.C. § 321(ff)(3)(B) drug-exclusion clause — NMN had been authorized for investigation as a new drug (Metro International Biotech's MIB-626 IND), with substantial clinical investigations made public before it was marketed as a supplement. Retailers pulled NMN products.
• September 29, 2025: The FDA reversed that position, concluding on a "race-to-market" finding that NMN was marketed as a supplement before the drug authorization — so the exclusion did not apply on the facts. Documented in industry compliance coverage (dicentra's analysis of the reversal; NutraIngredients reporting on the subsequent NDI reinstatement). Restrictions loosened.
• December 2, 2025: The FDA formally reinstated the NDI acknowledgment status for SyncoZymes (NDI 1247) and Kingdomway (NDI 1259). Eligibility restored — NMN remains a notified new dietary ingredient, back in the supplement lane. (NPA dismissed its lawsuit, D.D.C. No. 1:24-cv-02479, without prejudice.)

That is the status as of August 2026 — and the trajectory has been toward openness. This page carries a review-by date of March 31, 2027 precisely because "legal today" is a dated claim we keep current, not a permanent fact.

What the reversal opened up

What changed: NMN can again be marketed and sold as a dietary supplement in the U.S., subject to the normal supplement rules — NDI compliance, cGMP manufacturing, truthful labeling. For consumers, the practical result is simple: NMN is back on the market through normal retail channels.

What stayed the same:

• Disease claims remain prohibited. Nothing about the reversal permits marketing NMN to treat, cure, or prevent any disease or condition. The claims rules that govern every supplement govern NMN — which is how it should be.
• The science kept moving in NMN's favor on the biomarker. Human trials have examined NMN at doses of 250–900 mg/day and documented that oral NMN raises blood NAD+ levels [published human data — biomarker endpoint] — and a 2026 head-to-head against NR (Christen et al., n=65, 1,000 mg/day) found both arms roughly doubled blood NAD+ [published human data].
• State, platform, and payment-rail rules may differ. Marketplace and advertising policies often lag or exceed federal rules. Sellers shouldn't assume "federally permissible" means "permissible everywhere you operate."

Why there's no NMN product here — and what we sell instead

We sell no NMN, and that was true before, during, and after the exclusion episode. The reason is formulation logic, not regulation. NMN is a precursor: the body converts it into NAD+, and it works fine as a swallowed capsule — so a strip adds little for it. The InstaMed line skips the precursor step and delivers NAD+ directly in a dissolving strip — 100 mg per strip in the Energy SKU. Intact NAD+ does not survive the gut intact, which is exactly why a sublingual format is the interesting route for it. The molecule-size and gut-survival reasoning is laid out in the NAD+ pillar, and the precursor-versus-direct comparison is the honest way to frame the choice: precursors have the longer published human trial history; direct NAD+ in strip format is the newer, more direct idea.

A companion piece comparing NMN and NAD+ head-to-head is planned for a future batch; until then, the pillar above is the right starting point, and our NMN vs NR comparison covers the precursor side.

What the record shows — dated

Established, with dates: the 2022 exclusion position; the September 29, 2025 reversal; the December 2, 2025 NDI reinstatement restoring eligibility; the continued prohibition on disease claims for any supplement, NMN included; human trials showing oral NMN raises blood NAD+ (a biomarker result).

Still open: any proven health outcome from NMN supplementation; the permanence of the current regulatory position — it has moved once and could move again; state-level, marketplace, or international rules, which this page does not attempt to catalog.

The honest context, once

One passage, plainly: a legal-status page on a seller's site has an obvious conflict, and ours is that clarity about NMN costs us nothing, because we don't sell it — you should notice that. Sources with an NMN product to move have an incentive to read the reversal as vindication of the compound itself, and it isn't; it's a decision about which regulatory bucket NMN sits in. And the live consumer question was never only "is it legal" (it is, as of this writing) but "is there evidence it does anything for me" — where the biomarker data is solid and the outcomes data is still being written, for everyone selling it. That's the whole limit, and now you have it.

The bottom line

Yes — NMN is legal again: the restrictions loosened in late 2025 and supplement eligibility was restored, so the supplement lane is open. This page is date-stamped and re-reviewed on a set schedule, because the one thing we know about this status is that it can move — and we'll keep the date honest.

Since this line sells NAD+ directly rather than its precursor, the relevant product page is the NAD+ strips — the reasoning behind that choice is in the NAD+ pillar.

---

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

This content is for educational purposes only and is not medical advice. Consult a licensed healthcare provider before starting any new product. Individual results vary.